Abstract Library

#4613 Correlation of serum cytokeratin 18, ferritin, cancer antigen 125, and beta-2 microglobulin with tumour grade and stage in pancreatic neuroendocrine tumours

Introduction: Pancreatic neuroendocrine neoplasms (PNENs) remain challenging to diagnose, with limited reliable serum biomarkers available for early detection and prognostication.

Conference:

Presenting Author: Janas K

Authors: Janas K, Rosiek V, Kos-Kudła B,

Keywords: NEN, biomarker, analysis, diagnostic, pancreatic tumour,

#4568 Investigating the dual role of SNW1 in splicing and transcription to understand pancreatic neuroendocrine tumour progression

Introduction: Pancreatic neuroendocrine tumours (PanNETs) are classified into grades (G1-G3) based on mitotic rate, with higher grades exhibiting increased dedifferentiation and invasiveness. Despite the clinical significance of PanNETs progression, the underlying mechanisms remain largely unexplored. We have previously reported that altered alternative splicing plays an essential role in PanNETs progression, where SNW1, a key regulator of splicing and transcription, was found to be overexpressed in tumour tissue, correlating with higher grade and recurrence risk.

Conference:

Presenting Author: González-Pérez C

Authors: González-Pérez C, Simón-Lesnyak M, Blázquez-Encinas R, García Vioque V, Moreno Montilla M,

Keywords: pancreas, neuroendocrine tumour, progression, SNW1, splicing,

#4540 Retrospective analysis of somatostatin receptors expression in cohort of thoracic neuroendocrine neoplasms with immunohistochemistry method or PET/CT Ga68 DOTA-TATE

Introduction: Somatostatin receptors (SSTRs) expression in cohort of thoracic neuroendocrine neoplasms (NENs) is still not fully described. We attempted to evaluate the SSTR expression by IHC and PET/CT with Ga68 DOTA-TATE, as well as the sensitivity of both methods.

Conference:

Presenting Author: Evdokimova E

Authors: Evdokimova E, Vorobeva M, Zhulikov Y, Markovich A, Gorbunova V,

Keywords: NEN, thoracic, SSTR, IHC, DOTATATE, lung, thymus, mediastinum, LCNC, NET,

#4518 Efficacy and safety of cabozantinib (CABO) for advanced Grade 3 (G3) neuroendocrine tumours (NETs) after progression on prior therapy: Subgroup analysis of the phase III CABINET trial (Alliance A021602)

Introduction: Well-differentiated G3 NETs have been described as a distinct category recently, and randomised data regarding efficacy of therapy are scarce. In the phase 3 CABINET trial (NCT03375320), CABO significantly prolonged progression-free survival (PFS) compared with placebo (PB) in patients (pts) with advanced, previously treated, progressive well-differentiated extra-pancreatic NETs (epNETs) and pancreatic NETs (pNETs) of all grades (Chan et al., NEJM, 2024).

Conference:

Presenting Author: Strosberg J

Authors: Strosberg J, Zemla T, Geyer S, Pulsipher S, Behr S,

Keywords: cabozantinib, grade 3 neuroendocrine tumour, pancreatic neuroendocrine tumour, extra-pancreatic neuroendocrine tumour,

#4506 Matching adjusted indirect comparison (MAIC) of [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) vs. streptozocin-based chemotherapies (STZ-BC) as first-line (1L) treatment for advanced grade 2/3 (G2/G3) pancreatic NETs (pNETs)

Introduction: The NETTER-2 trial showed improved progression-free survival (PFS) with 1L 177Lu-DOTATATE vs. high dose octreotide in advanced G2/G3 pNETs. No published evidence exists comparing 177Lu-DOTATATE with other recommended 1L treatments, such as STZ-BC, hence indirect comparisons need to be conducted.

Conference:

Presenting Author: Navalkissoor S

Authors: Navalkissoor S, Capdevila J, Deshayes E, Gerard L, Srirajaskanthan R,

Keywords: pancreatic neuroendocrine tumour, [177lu]lu-dotatate, streptozocin, 5-fluorouracil, matching adjusted indirect comparison,